← Eichor
Study identifier: NCT07476339 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

Condition: HIV -1 Infection · HIV (Human Immunodeficiency Virus) · HIV  ·  Sponsor: CAN Community Health

PhasePhase 4
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care. The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines. Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain contr…

This description comes directly from the study's public registry record.

Talk to the study team

Prerak Shukla, MD  ·  941-366-0134  ·  pshukla@cancommunityhealth.org

Miranda Townsend  ·  +44 7709-514-696  ·  biktarvy.rapidrestartstudy@costellomedical.com

Always discuss trial participation with your own doctor first.

Locations (10)

CAN Community HealthClearwater, Florida, United StatesRecruiting
Midway Specialty Care CenterFt. Pierce, Florida, United StatesRecruiting
CAN Community HealthJacksonville, Florida, United StatesRecruiting
CAN Community HealthOrlando, Florida, United StatesRecruiting
Midway Specialty Care CenterOrlando, Florida, United StatesNot Yet Recruiting
CAN Community HealthTampa, Florida, United StatesRecruiting
Midway Specialty Care CenterTemple Terrace, Florida, United StatesRecruiting
Midway Specialty Care CenterWest Palm Beach, Florida, United StatesRecruiting
Midway Specialty Care CenterWilton Manors, Florida, United StatesNot Yet Recruiting
CAN Community HealthLas Vegas, Nevada, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07476339